Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer

Murielle Mimeault, Satyanarayana Rachagani, Sakthivel Muniyan, Parthasarathy Seshacharyulu, Sonny L. Johansson, Kaustubh Datta, Ming-Fong Lin, Surinder Kumar Batra

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The establishment of docetaxel-based chemotherapeutic treatments has improved the survival of castration-resistant prostate cancer (CRPC) patients. However, most patients develop resistance supporting the development of therapy. The current study was undertaken to establish the therapeutic benefit to target hedgehog signaling cascade using GDC-0449 to improve the efficacy of chemotherapeutic drug, docetaxel. Here, we show that the combination of GDC-0449 plus docetaxel inhibited the proliferation of WPE1-NB26 cells and PC3 cells via a blockade of G1 and G2M phases. The combined treatment significantly inhibited PC cell migration in vitro. Moreover, the apoptotic effect induced by GDC-0449 plus docetaxel on PC3 cells was mediated, at least partly, via the mitochondrial membrane depolarization, H2O2 production and caspase cascade activation. Interestingly, GDC-0449 was effective at inhibiting the prostasphere formation, inducing the prostasphere disintegration and apoptotic death of side population (SP) from PC3 cells and reversing the resistance of SP cells to docetaxel. In addition, GDC-0449 plus docetaxel also have shown a greater anti-tumoral growth inhibitory effect on PC3 cell xenografts. These findings support the use of the hedgehog inhibitor GDC-0449, which is currently in clinical trials, for improving the anticarcinogenic efficacy of docetaxel-based chemotherapeutic treatments against locally advanced, AI and metastatic PC.

Original languageEnglish (US)
Pages (from-to)3887-3903
Number of pages17
JournalOncotarget
Volume6
Issue number6
DOIs
StatePublished - Jan 1 2015

Fingerprint

docetaxel
HhAntag691
Anticarcinogenic Agents
Prostatic Neoplasms
Side-Population Cells
Therapeutics
Castration
G1 Phase
Mitochondrial Membranes
Caspases
Heterografts
Cell Movement

Keywords

  • Docetaxel
  • GDC-0449
  • Hedgehog signaling pathway
  • PC stem/progenitor cells and PC3 xenograft
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer. / Mimeault, Murielle; Rachagani, Satyanarayana; Muniyan, Sakthivel; Seshacharyulu, Parthasarathy; Johansson, Sonny L.; Datta, Kaustubh; Lin, Ming-Fong; Batra, Surinder Kumar.

In: Oncotarget, Vol. 6, No. 6, 01.01.2015, p. 3887-3903.

Research output: Contribution to journalArticle

Mimeault, Murielle ; Rachagani, Satyanarayana ; Muniyan, Sakthivel ; Seshacharyulu, Parthasarathy ; Johansson, Sonny L. ; Datta, Kaustubh ; Lin, Ming-Fong ; Batra, Surinder Kumar. / Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer. In: Oncotarget. 2015 ; Vol. 6, No. 6. pp. 3887-3903.
@article{e2a9a3d3a5244b6da1d185e1859ea1c5,
title = "Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer",
abstract = "The establishment of docetaxel-based chemotherapeutic treatments has improved the survival of castration-resistant prostate cancer (CRPC) patients. However, most patients develop resistance supporting the development of therapy. The current study was undertaken to establish the therapeutic benefit to target hedgehog signaling cascade using GDC-0449 to improve the efficacy of chemotherapeutic drug, docetaxel. Here, we show that the combination of GDC-0449 plus docetaxel inhibited the proliferation of WPE1-NB26 cells and PC3 cells via a blockade of G1 and G2M phases. The combined treatment significantly inhibited PC cell migration in vitro. Moreover, the apoptotic effect induced by GDC-0449 plus docetaxel on PC3 cells was mediated, at least partly, via the mitochondrial membrane depolarization, H2O2 production and caspase cascade activation. Interestingly, GDC-0449 was effective at inhibiting the prostasphere formation, inducing the prostasphere disintegration and apoptotic death of side population (SP) from PC3 cells and reversing the resistance of SP cells to docetaxel. In addition, GDC-0449 plus docetaxel also have shown a greater anti-tumoral growth inhibitory effect on PC3 cell xenografts. These findings support the use of the hedgehog inhibitor GDC-0449, which is currently in clinical trials, for improving the anticarcinogenic efficacy of docetaxel-based chemotherapeutic treatments against locally advanced, AI and metastatic PC.",
keywords = "Docetaxel, GDC-0449, Hedgehog signaling pathway, PC stem/progenitor cells and PC3 xenograft, Prostate cancer",
author = "Murielle Mimeault and Satyanarayana Rachagani and Sakthivel Muniyan and Parthasarathy Seshacharyulu and Johansson, {Sonny L.} and Kaustubh Datta and Ming-Fong Lin and Batra, {Surinder Kumar}",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.2932",
language = "English (US)",
volume = "6",
pages = "3887--3903",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "6",

}

TY - JOUR

T1 - Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer

AU - Mimeault, Murielle

AU - Rachagani, Satyanarayana

AU - Muniyan, Sakthivel

AU - Seshacharyulu, Parthasarathy

AU - Johansson, Sonny L.

AU - Datta, Kaustubh

AU - Lin, Ming-Fong

AU - Batra, Surinder Kumar

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The establishment of docetaxel-based chemotherapeutic treatments has improved the survival of castration-resistant prostate cancer (CRPC) patients. However, most patients develop resistance supporting the development of therapy. The current study was undertaken to establish the therapeutic benefit to target hedgehog signaling cascade using GDC-0449 to improve the efficacy of chemotherapeutic drug, docetaxel. Here, we show that the combination of GDC-0449 plus docetaxel inhibited the proliferation of WPE1-NB26 cells and PC3 cells via a blockade of G1 and G2M phases. The combined treatment significantly inhibited PC cell migration in vitro. Moreover, the apoptotic effect induced by GDC-0449 plus docetaxel on PC3 cells was mediated, at least partly, via the mitochondrial membrane depolarization, H2O2 production and caspase cascade activation. Interestingly, GDC-0449 was effective at inhibiting the prostasphere formation, inducing the prostasphere disintegration and apoptotic death of side population (SP) from PC3 cells and reversing the resistance of SP cells to docetaxel. In addition, GDC-0449 plus docetaxel also have shown a greater anti-tumoral growth inhibitory effect on PC3 cell xenografts. These findings support the use of the hedgehog inhibitor GDC-0449, which is currently in clinical trials, for improving the anticarcinogenic efficacy of docetaxel-based chemotherapeutic treatments against locally advanced, AI and metastatic PC.

AB - The establishment of docetaxel-based chemotherapeutic treatments has improved the survival of castration-resistant prostate cancer (CRPC) patients. However, most patients develop resistance supporting the development of therapy. The current study was undertaken to establish the therapeutic benefit to target hedgehog signaling cascade using GDC-0449 to improve the efficacy of chemotherapeutic drug, docetaxel. Here, we show that the combination of GDC-0449 plus docetaxel inhibited the proliferation of WPE1-NB26 cells and PC3 cells via a blockade of G1 and G2M phases. The combined treatment significantly inhibited PC cell migration in vitro. Moreover, the apoptotic effect induced by GDC-0449 plus docetaxel on PC3 cells was mediated, at least partly, via the mitochondrial membrane depolarization, H2O2 production and caspase cascade activation. Interestingly, GDC-0449 was effective at inhibiting the prostasphere formation, inducing the prostasphere disintegration and apoptotic death of side population (SP) from PC3 cells and reversing the resistance of SP cells to docetaxel. In addition, GDC-0449 plus docetaxel also have shown a greater anti-tumoral growth inhibitory effect on PC3 cell xenografts. These findings support the use of the hedgehog inhibitor GDC-0449, which is currently in clinical trials, for improving the anticarcinogenic efficacy of docetaxel-based chemotherapeutic treatments against locally advanced, AI and metastatic PC.

KW - Docetaxel

KW - GDC-0449

KW - Hedgehog signaling pathway

KW - PC stem/progenitor cells and PC3 xenograft

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84924266993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924266993&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.2932

DO - 10.18632/oncotarget.2932

M3 - Article

VL - 6

SP - 3887

EP - 3903

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 6

ER -